Dynavax Technologies Corp’s recent filing unveils that its Director Myers Scott Dunseth acquired Company’s shares for reported $41116.0 on Aug 22 ’25. In the deal valued at $10.82 per share,3,800 shares were bought. As a result of this transaction, Myers Scott Dunseth now holds 35,004 shares worth roughly $0.35 million.
Then, Deep Track Biotechnology Maste sold 1,094,994 shares, generating $12,077,784 in total proceeds. Upon selling the shares at $11.03, the 10% Owner now owns 16,696,492 shares.
Before that, Deep Track Biotechnology Maste sold 970,143 shares. Dynavax Technologies Corp shares valued at $10,273,814 were divested by the 10% Owner at a price of $10.59 per share. As a result of the transaction, Deep Track Biotechnology Maste now holds 15,726,349 shares, worth roughly $156.63 million.
Goldman downgraded its Dynavax Technologies Corp [DVAX] rating to a Sell from a a Neutral in a research note published on February 11, 2025; the price target was decreased to $12 from $15. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in early February with a ‘”a Neutral”‘ rating. JMP Securities began covering DVAX with “Mkt outperform” recommendation on September 27, 2022.
Price Performance Review of DVAX
On Friday, Dynavax Technologies Corp [NASDAQ:DVAX] saw its stock fall -3.77% to $9.96. Over the last five days, the stock has lost -1.39%. Dynavax Technologies Corp shares have fallen nearly -6.30% since the year began. Nevertheless, the stocks have fallen -22.00% over the past one year.
How much short interest is there in Dynavax Technologies Corp?
A steep rise in short interest was recorded in Dynavax Technologies Corp stocks on 2025-09-30, dropping by -0.62 million shares to a total of 13.48 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 14.1 million shares. There was a decline of -4.58%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 06, 2021 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $19 price target.
